Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

557 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic ability of mid-term worsening renal function after percutaneous coronary intervention: findings from the SHINANO registry.
Okina Y, Miura T, Senda K, Taki M, Kobayashi M, Kanai M, Okuma Y, Yanagisawa T, Hashizume N, Otagiri K, Shoin K, Watanabe N, Ebisawa S, Karube K, Nakajima H, Saigusa T, Miyashita Y, Kashiwagi D, Machida K, Abe N, Tachibana T, Kanzaki Y, Maruyama T, Nomi H, Sakai T, Yui H, Mochidome T, Kobayashi T, Kasai T, Ikeda U, Kuwahara K. Okina Y, et al. Among authors: okuma y. Heart Vessels. 2021 Oct;36(10):1496-1505. doi: 10.1007/s00380-021-01837-8. Epub 2021 Apr 7. Heart Vessels. 2021. PMID: 33825976 Free PMC article.
Immunotherapy for patients with advanced non-small cell lung cancer harboring oncogenic driver alterations other than EGFR: a multicenter real-world analysis.
Tian T, Li Y, Li J, Xu H, Fan H, Zhu J, Wang Y, Peng F, Gong Y, Du Y, Yan X, He X, Cali Daylan AE, Pircher A, Neibart SS, Okuma Y, Hong MH, Huang M, Lu Y. Tian T, et al. Among authors: okuma y. Transl Lung Cancer Res. 2024 Apr 29;13(4):861-874. doi: 10.21037/tlcr-24-116. Epub 2024 Apr 24. Transl Lung Cancer Res. 2024. PMID: 38736501 Free PMC article.
Efficacy and safety of chemoimmunotherapy in advanced non-small cell lung cancer patients with antibiotics-induced dysbiosis: a propensity-matched real-world analysis.
Tamura K, Okuma Y, Nomura S, Fukuda A, Masuda K, Matsumoto Y, Shinno Y, Yoshida T, Goto Y, Horinouchi H, Yamamoto N, Ohe Y. Tamura K, et al. Among authors: okuma y. J Cancer Res Clin Oncol. 2024 Apr 26;150(4):216. doi: 10.1007/s00432-024-05649-x. J Cancer Res Clin Oncol. 2024. PMID: 38668936 Free PMC article.
Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: Results from the multicenter, phase 2 REMORA trial.
Niho S, Sato J, Satouchi M, Itoh S, Okuma Y, Mizugaki H, Murakami H, Fujisaka Y, Kozuki T, Nakamura K, Machida R, Ohe Y, Tamai T, Ikezawa H, Yamamoto N. Niho S, et al. Among authors: okuma y. Lung Cancer. 2024 May;191:107557. doi: 10.1016/j.lungcan.2024.107557. Epub 2024 Mar 30. Lung Cancer. 2024. PMID: 38626709 Free article. Clinical Trial.
Clinical significance of inter-assay discrepancy in PD-L1 evaluation for the efficacy of pembrolizumab in advanced NSCLC with high PD-L1 expression.
Miyakoshi J, Yoshida T, Kashima J, Shirasawa M, Torasawa M, Matsumoto Y, Masuda K, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Shiraishi K, Kohno T, Yamamoto N, Yatabe Y, Suzuki T, Ohe Y. Miyakoshi J, et al. Among authors: okuma y. Lung Cancer. 2024 May;191:107788. doi: 10.1016/j.lungcan.2024.107788. Epub 2024 Apr 6. Lung Cancer. 2024. PMID: 38593478
Artemis: A Multicenter, Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of First-Line Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas.
Okuma Y, Nomura S, Sakakibara-Konishi J, Tsukita Y, Murakami S, Hosomi Y, Tambo Y, Kogure Y, Yoshioka H, Tamiya M, Ninomiya K, Iwama E. Okuma Y, et al. Clin Lung Cancer. 2024 Feb 8:S1525-7304(24)00013-5. doi: 10.1016/j.cllc.2024.02.002. Online ahead of print. Clin Lung Cancer. 2024. PMID: 38413246
Efficacy of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Metastatic Non-Small Cell Lung Cancer Patients with Poor Performance Status and Epidermal Growth Factor Receptor Mutations: Findings from the Japanese Lung Cancer Registry Database.
Okuma Y, Shintani Y, Sekine I, Shukuya T, Takayama K, Inoue A, Okamoto I, Kiura K, Yamamoto N, Kawaguchi T, Miyaoka E, Yoshino I, Date H. Okuma Y, et al. Clin Lung Cancer. 2024 Feb 2:S1525-7304(24)00007-X. doi: 10.1016/j.cllc.2024.01.005. Online ahead of print. Clin Lung Cancer. 2024. PMID: 38360497
557 results